Accustem Sciences (ACUT) Net Equity Issued and Repurchased (2022)
Accustem Sciences (ACUT) posted quarterly Net Equity Issued and Repurchased of -$187.0 for Q3 2022, down 200.0% quarter-over-quarter from $187.0 in Q2 2022.
Accustem Sciences (ACUT) Net Equity Issued and Repurchased (2022) Analysis & Trends
Accustem Sciences (ACUT) has reported Net Equity Issued and Repurchased for 1 consecutive years, with -$187.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Net Equity Issued and Repurchased changed N/A year-over-year to -$187.0; the TTM figure through Dec 2022 stood at $2.7 million (changed N/A YoY), while the FY2022 annual figure was $2.7 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased eased to -$187.0 in Q3 2022 per ACUT's latest filing, from $187.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $2.7 million in Q1 2022 and bottomed at -$187.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -187.00 |
| Sep 30, 2022 | -187.00 |
| Jun 30, 2022 | 187.00 |
| Jun 30, 2022 | 187.00 |
| Mar 31, 2022 | 2.68 Mn |
| Mar 31, 2022 | 2.68 Mn |